Relmada Therapeutics Inc Cash Flow Conversion Efficiency
Relmada Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has a cash flow conversion efficiency ratio of -0.069x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.07 Million) by net assets ($218.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Relmada Therapeutics Inc (2012–2025)
Cash flow conversion efficiency of Relmada Therapeutics Inc from 2012 to 2025. This chart illustrates how Relmada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Relmada Therapeutics Inc share price for real-time trading data and today's change.
Relmada Therapeutics Inc Cash Flow Conversion Ratio Explained
Relmada Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Relmada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relmada Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Relmada Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
-0.496x |
|
Beijing Capital International Airport Company Limited
F:BJ1
|
-0.023x |
|
PARKEN Sport & Entertainment
CO:PARKEN
|
0.252x |
|
Dagang Nexchange Bhd
KLSE:4456
|
0.009x |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
N/A |
|
Meteoric Resources NL
F:RNF
|
-0.820x |
|
Nanning Department Store Co Ltd
SHG:600712
|
0.000x |
|
Banco Santander Brasil SA
BA:BSBR
|
0.309x |
Annual Cash Flow Conversion Efficiency for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Relmada Therapeutics Inc from 2012 to 2025. Review free cash flow generation of Relmada Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.51 Million | $-45.79 Million | -0.529x | +63.68% |
| 2024-12-31 | $35.52 Million | $-51.76 Million | -1.457x | -140.74% |
| 2023-12-31 | $85.36 Million | $-51.66 Million | -0.605x | +18.12% |
| 2022-12-31 | $140.44 Million | $-103.80 Million | -0.739x | -67.55% |
| 2021-12-31 | $208.26 Million | $-91.87 Million | -0.441x | -67.49% |
| 2020-12-31 | $105.58 Million | $-27.81 Million | -0.263x | -251866.34% |
| 2019-12-31 | $115.68 Million | $-12.09K | 0.000x | -100.01% |
| 2018-12-31 | $-5.51 Million | $-6.00 Million | 1.089x | +124.59% |
| 2017-12-31 | $1.46 Million | $-6.47 Million | -4.428x | -137.26% |
| 2016-12-31 | $7.04 Million | $-13.14 Million | -1.866x | -1.33% |
| 2015-12-31 | $8.81 Million | $-16.23 Million | -1.842x | 0.00% |
| 2014-12-31 | $8.81 Million | $-16.23 Million | -1.842x | -191.19% |
| 2014-06-30 | $-1.11 Million | $-2.24 Million | 2.020x | +18788.61% |
| 2013-12-31 | $-1.11 Million | $-11.86K | 0.011x | +101.61% |
| 2012-12-31 | $11.36K | $-7.57K | -0.666x | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more